Paper list

2022-07-04

Ohashi H Hishiki T Akazawa D Kim KS Woo J Shionoya K Tsuchimoto K Iwanami S Moriyama S Kinoshita H Yamada S Kuroda Y Yamamoto T Kishida N Watanabe S Hasegawa H Ebihara H Suzuki T Maeda K Fukushi S Takahashi Y Iwami S Watashi K

2022-04

Kumata R Iwanami S Mar KB Kakizoe Y Misawa N Nakaoka S Koyanagi Y Perelson AS Schoggins JW Iwami S Sato K

2022-03-26

Yoshida M Kobashi Y Kawamura T Shimazu Y Nishikawa Y Omata F Zhao T Yamamoto C Kaneko Y Nakayama A Takita M Ito N Kawashima M Sugiura S Shibuya K Iwami S Kim K Iwanami S Kodama T Tsubokura M

2021-10

Kim KS Iwanami S Oda T Fujita Y Kuba K Miyazaki T Ejima K Iwami S

2021-07-27

Jeong YD Ejima K Kim KS Iwanami S Bento AI Fujita Y Jung IH Aihara K Watashi K Miyazaki T Wakita T Iwami S Ajelli M

2021-07

Iwanami S Ejima K Kim KS Noshita K Fujita Y Miyazaki T Kohno S Miyazaki Y Morimoto S Nakaoka S Koizumi Y Asai Y Aihara K Watashi K Thompson RN Shibuya K Fujiu K Perelson AS Iwami S Wakita T

2021-06

Ejima K Kim KS Ludema C Bento AI Iwanami S Fujita Y Ohashi H Koizumi Y Watashi K Aihara K Nishiura H Iwami S

2021-04-30

Shionoya K Yamasaki M Iwanami S Ito Y Fukushi S Ohashi H Saso W Tanaka T Aoki S Kuramochi K Iwami S Takahashi Y Suzuki T Muramatsu M Takeda M Wakita T Watashi K

2021-04-23

Ohashi H Watashi K Saso W Shionoya K Iwanami S Hirokawa T Shirai T Kanaya S Ito Y Kim KS Nomura T Suzuki T Nishioka K Ando S Ejima K Koizumi Y Tanaka T Aoki S Kuramochi K Suzuki T Hashiguchi T Maenaka K Matano T Muramatsu M Saijo M Aihara K Iwami S Takeda M McKeating JA Wakita T

2021-04

Ejima K Kim KS Iwanami S Fujita Y Li M Zoh RS Aihara K Miyazaki T Wakita T Iwami S

2021-03

Kim KS Ejima K Iwanami S Fujita Y Ohashi H Koizumi Y Asai Y Nakaoka S Watashi K Aihara K Thompson RN Ke R Perelson AS Iwami S

2021

Akao M Woo J Iwami S Iwanami S

2020-07

Iwanami S Kitagawa K Ohashi H Asai Y Shionoya K Saso W Nishioka K Inaba H Nakaoka S Wakita T Diekmann O Iwami S Watashi K

2020-06

Ono C Fukuhara T Li S Wang J Sato A Izumi T Fauzyah Y Yamamoto T Morioka Y Dokholyan NV Standley DM Matsuura Y

2019-10-21

Hara A Iwanami S Ito Y Miura T Nakaoka S Iwami S

2017-04-21

Iwanami S Kakizoe Y Morita S Miura T Nakaoka S Iwami S

アイウエオ

書類用論文リスト

論文

Hyeongki Park, Raiki Yoshimura, Shoya Iwanami, Kwang Su Kim, Keisuke Ejima, Naotoshi Nakamura, Kazuyuki Aihara, Yoshitsugu Miyazaki, Takashi Umeyama, Ken Miyazawa, Takeshi Morita, Koichi Watashi, Christopher B. Brooke, Ruian Ke, Shingo Iwami, Taiga Miyazaki. Stratification of viral shedding patterns in saliva of COVID-19 patients. eLife (2024) 13:RP96032. DOI: 10.7554/eLife.96032.1
Teiko Kawahigashi, Shoya Iwanami, Munetomo Takahashi, Joydeep Bhadury, Shingo Iwami, Satoshi Yamazaki. Age-related changes in the hematopoietic stem cell pool revealed via quantifying the balance of symmetric and asymmetric divisions. PLOS ONE (2024) 19(1): e0292575. DOI: 10.1371/journal.pone.0292575
Taiga Miyazaki, Naoki Hosogaya, Yuri Fukushige, Sachiko Takemori, Shinpei Morimoto, Hiroshi Yamamoto, Makoto Hori, Yoshihito Ozawa, Yuki Shiko, Yosuke Inaba, Tomoya Kurokawa, Hideki Hanaoka, Shoya Iwanami, Kwangsu Kim, Shingo Iwami, Koichi Watashi, Ken Miyazawa, Takashi Umeyama, Satoshi Yamagoe, Yoshitsugu Miyazaki, Takaji Wakita, Makoto Sumiyoshi, Tatsuro Hirayama, Koichi Izumikawa, Katsunori Yanagihara, Hiroshi Mukae, Hitoshi Kawasuji, Yoshihiro Yamamoto, Norihito Tarumoto, Hiroshi Ishii, Hideaki Ohno, Kazuhiro Yatera, Hiroshi Kakeya, Yoshiko Kichikawa, Yasuyuki Kato, Tetsuya Matsumoto, Makoto Saito, Hiroshi Yotsuyanagi, Shigeru Kohno. A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19. Microbiology Spectrum (2023) e04311-22. DOI: 10.1128/spectrum.04311-22
Shiho Torii, Kwang Su Kim, Jun Koseki, Rigel Suzuki, Shoya Iwanami, Yasuhisa Fujita, Yong Dam Jeong, Jumpei Ito, Hiroyuki Asakura, Mami Nagashima, Kenji Sadamasu, Kazuhisa Yoshimura, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Kei Sato, Yoshiharu Matsuura, Teppei Shimamura, Shingo Iwami, Takasuke Fukuhara. Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir. PLOS Pathogens (2023) 19(3): e1011231. DOI: 10.1371/journal.ppat.1011231
Daisuke Akazawa, Hirofumi Ohashi, Takayuki Hishiki, Takeshi Morita, Shoya Iwanami, Kwang Su Kim, Yong Dam Jeong, Eun-Sil Park, Michiyo Kataoka, Kaho Shionoya, Junki Mifune, Kana Tsuchimoto, Shinjiro Ojima, Aa Haeruman Azam, Shogo Nakajima, Hyeongki Park, Tomoki Yoshikawa, Masayuki Shimojima, Kotaro Kiga, Shingo Iwami, Ken Maeda, Tadaki Suzuki, Hideki Ebihara, Yoshimasa Takahashi, Koichi Watashi. Potential anti-mpox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments. The Journal of Infectious Diseases (2023) jiad058. DOI: 10.1093/infdis/jiad058
Daiki Tatematsu, Marwa Akao, Hyeongki Park, Shingo Iwami, Keisuke Ejima, Shoya Iwanami*. Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors. Journal of Theoretical Biology (2023) 561:111403. DOI: 10.1016/j.jtbi.2022.111403
Yong Dam Jeong, Keisuke Ejima, Kwang Su Kim, Woo Joohyeon, Shoya Iwanami, Yasuhisa Fujita, Il Hyo Jung, Kazuyuki Aihara, Kenji Shibuya, Shingo Iwami, Ana I. Bento, Marco Ajelli. Designing isolation guidelines for COVID-19 patients with rapid antigen tests. Nature Communications (2022) 13, 4910. DOI: 10.1038/s41467-022-32663-9
Keisuke Ejima, Kwang Su Kim, Ana I. Bento, Shoya Iwanami, Yasuhisa Fujita, Kazuyuki Aihara, Kenji Shibuya, Shingo Iwami. Estimation of timing of infection from longitudinal SARS-CoV-2 viral load data: mathematical modelling study. BMC Infectious Diseases (2022) 22, 656. DOI: 10.1186/s12879-022-07646-2
Hirofumi Ohashi, Takayuki Hishiki, Daisuke Akazawa, Kwang Su Kim, Joohyeon Woo, Kaho Shionoya, Kana Tsuchimoto, Shoya Iwanami, Saya Moriyama, Hitomi Kinoshita, Souichi Yamada, Yudai Kuroda, Tsukasa Yamamoto, Noriko Kishida, Shinji Watanabe, Hideki Hasegawa, Hideki Ebihara, Tadaki Suzuki, Ken Maeda, Shuetsu Fukushi, Yoshimasa Takahashi, Shingo Iwami, Koichi Watashi. Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2. Antiviral Research (2022) 105372. DOI: 10.1016/j.antiviral.2022.105372
Ryuichi Kumata, Shoya Iwanami, Katrina B. Mar, Yusuke Kakizoe, Naoko Misawa, Shinji Nakaoka, Yoshio Koyanagi, Alan S. Perelson, John W. Schoggins, Shingo Iwami*, Kei Sato*. Antithetic effect of interferon-α on cell-free and cell-to-cell HIV-1 infection. PLOS Computational Biology (2022) 18(4): e1010053. DOI: 10.1371/journal.pcbi.1010053
Makoto Yoshida, Yurie Kobashi, Takeshi Kawamura, Yuzo Shimazu, Yoshitaka Nishikawa, Fumiya Omata, Tianchen Zhao, Chika Yamamoto, Yudai Kaneko, Aya Nakayama, Morihito Takita, Naomi Ito, Moe Kawashima, Sota Sugiura, Kenji Shibuya, Shingo Iwami, Kwangsu Kim, Shoya Iwanami, Tatsuhiko Kodama, Masaharu Tsubokura. Factors Associated with COVID-19 Vaccine Booster Hesitancy: A Retrospective Cohort Study, Fukushima Vaccination Community Survey. Vaccines (2022) 10(4):515. DOI: 10.3390/vaccines10040515
Marwa Akao, Joohyeon Woo, Shingo Iwami, Shoya Iwanami*. Detection of significant antiviral drug effects on COVID-19 using viral load and PCR-positive rate in randomized controlled trials. Translational and Regulatory Sciences (2021) Volume 3 Issue 3 Pages 85-88. DOI: 10.33611/trs.2021-025
Kwang Su Kim, Shoya Iwanami, Takafumi Oda, Yasuhisa Fujita, Keiji Kuba, Taiga Miyazaki, Keisuke Ejima‡*, Shingo Iwami‡*. Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection. Life Science Alliance (2021) 4 (10) e202101049. DOI: 10.26508/lsa.202101049
Yong Dam Jeong, Keisuke Ejima†*, Kwang Su Kim, Shoya Iwanami, Ana I Bento, Yasuhisa Fujita, Il Hyo Jung, Kazuyuki Aihara, Koichi Watashi, Taiga Miyazaki, Takaji Wakita, Shingo Iwami*, Marco Ajelli. Revisiting the guidelines for ending isolation for COVID-19 patients. eLife (2021) 10:e69340. DOI: 10.7554/eLife.69340
Shoya Iwanami, Keisuke Ejima†*, Kwang Su Kim, Koji Noshita, Yasuhisa Fujita, Taiga Miyazaki, Shigeru Kohno, Yoshitsugu Miyazaki, Shimpei Morimoto, Shinji Nakaoka, Yoshiki Koizumi, Yusuke Asai, Kazuyuki Aihara, Koichi Watashi, Robin N. Thompson, Kenji Shibuya, Katsuhito Fujiu, Alan S. Perelson, Shingo Iwami‡*, Takaji Wakita. Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study. PLOS Medicine (2021) 18(7):e1003660. DOI: doi.org/10.1371/journal.pmed.1003660
Kaho Shionoya, Masako Yamasaki, Shoya Iwanami, Yusuke Ito, Shuetsu Fukushi, Hirofumi Ohashi, Wakana Saso, Tomohiro Tanaka, Shin Aoki, Kouji Kuramochi, Shingo Iwami, Yoshimasa Takahashi, Tadaki Suzuki, Masamichi Muramatsu, Makoto Takeda, Takaji Wakita and Koichi Watashi. Mefloquine, a potent anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) drug as an entry inhibitor in vitro. Frontiers in Microbiology (2021) 12:651403. DOI: 10.3389/fmicb.2021.651403
Keisuke Ejima, Kwang Su Kim, Shoya Iwanami, Yasuhisa Fujita, Ming Li, Roger S. Zoh, Kazuyuki Aihara, Taiga Miyazaki, Takaji Wakita and Shingo Iwami (These authors contributed equally to this work.). Time variation in the probability of failing to detect a case of polymerase chain reaction testing for SARS-CoV-2 as estimated from a viral dynamics model. Journal of the Royal Society Interface (2021) 18: 20200947. 20200947.. DOI: 10.1098/rsif.2020.0947
Keisuke Ejima, Kwang Su Kim, Christina Ludema, Ana I. Bento, Shoya Iwanami, Yasuhisa Fujita, Hirofumi Ohashi, Yoshiki Koizumi, Koichi Watashi, Kazuyuki Aihara, Hiroshi Nishiura and Shingo Iwami. Estimation of the incubation period of COVID-19 using viral load data. Epidemics (2021) 100454. DOI: 10.1016/j.epidem.2021.100454
Hirofumi Ohashi, Koichi Watashi, Wakana Saso, Kaho Shionoya, Shoya Iwanami, Takatsugu Hirokawa, Tsuyoshi Shirai, Shigehiko Kanaya, Yusuke Ito, Kwang Su Kim, Takao Nomura, Tateki Suzuki, Kazane Nishioka, Shuji Ando, Keisuke Ejima, Yoshiki Koizumi, Tomohiro Tanaka, Shin Aoki, Kouji Kuramochi, Tadaki Suzuki, Takao Hashiguchi, Katsumi Maenaka, Tetsuro Matano, Masamichi Muramatsu, Masayuki Saijo, Kazuyuki Aihara, Shingo Iwami, Makoto Takeda, Jane A. McKeating and Takaji Wakita. Potential anti-COVID-19 agents, Cepharanthine and Nelfinavir, and their usage for combination treatment. iScience (2021) 102367. DOI: 10.1016/j.isci.2021.102367
Kwang Su Kim†, Keisuke Ejima†, Shoya Iwanami, Yasuhisa Fujita, Hirofumi Ohashi, Yoshiki Koizumi, Yusuke Asai, Shinji Nakaoka, Koichi Watashi, Kazuyuki Aihara, Robin N. Thompson, Ruian Ke, Alan S. Perelson and Shingo Iwami. A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. PLOS Biology (2021) 19(3): e3001128. DOI: 10.1371/journal.pbio.3001128
Shoya Iwanami†, Kosaku Kitagawa†, Hirofumi Ohashi, Yusuke Asai, Kaho Shionoya, Wakana Saso, Kazane Nishioka, Hisashi Inaba, Shinji Nakaoka, Takaji Wakita, Odo Diekmann, Shingo Iwami and Koichi Watashi. Should a viral genome stay in the host cell or leave? A quantitative dynamics study of how hepatitis C virus deals with this dilemma. PLOS Biology (2020) 18(7): e3000562. DOI: 10.1371/journal.pbio.3000562
Hara A., Iwanami S., Ito Y., Miura T., Nakaoka S., and Iwami S.. Revealing uninfected and infected target cell dynamics from peripheral blood data in highly and less pathogenic simian/human immunodeficiency virus infected Rhesus macaque. Journal of Theoretical Biology (2019) 479:29-36. DOI: 10.1016/j.jtbi.2019.07.005
Iwanami S., Kakizoe Y., Morita S., Miura T., Nakaoka S., and Iwami S.. A highly pathogenic simian/human immunodeficiency virus effectively produces infectious virions compared with a less pathogenic virus in cell culture. Theoretical Biology and Medical Modeling (2017) 14:9. DOI: 10.1186/s12976-017-0055-8

論文

Hyeongki Park, Raiki Yoshimura, Shoya Iwanami, Kwang Su Kim, Keisuke Ejima, Naotoshi Nakamura, Kazuyuki Aihara, Yoshitsugu Miyazaki, Takashi Umeyama, Ken Miyazawa, Takeshi Morita, Koichi Watashi, Christopher B. Brooke, Ruian Ke, Shingo Iwami, Taiga Miyazaki. Stratification of viral shedding patterns in saliva of COVID-19 patients. eLife. 13:RP96032. (2024)
Teiko Kawahigashi, Shoya Iwanami, Munetomo Takahashi, Joydeep Bhadury, Shingo Iwami, Satoshi Yamazaki. Age-related changes in the hematopoietic stem cell pool revealed via quantifying the balance of symmetric and asymmetric divisions. PLOS ONE. 19(1): e0292575. (2024)
Taiga Miyazaki, Naoki Hosogaya, Yuri Fukushige, Sachiko Takemori, Shinpei Morimoto, Hiroshi Yamamoto, Makoto Hori, Yoshihito Ozawa, Yuki Shiko, Yosuke Inaba, Tomoya Kurokawa, Hideki Hanaoka, Shoya Iwanami, Kwangsu Kim, Shingo Iwami, Koichi Watashi, Ken Miyazawa, Takashi Umeyama, Satoshi Yamagoe, Yoshitsugu Miyazaki, Takaji Wakita, Makoto Sumiyoshi, Tatsuro Hirayama, Koichi Izumikawa, Katsunori Yanagihara, Hiroshi Mukae, Hitoshi Kawasuji, Yoshihiro Yamamoto, Norihito Tarumoto, Hiroshi Ishii, Hideaki Ohno, Kazuhiro Yatera, Hiroshi Kakeya, Yoshiko Kichikawa, Yasuyuki Kato, Tetsuya Matsumoto, Makoto Saito, Hiroshi Yotsuyanagi, Shigeru Kohno. A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19. Microbiology Spectrum. e04311-22. (2023)
Shiho Torii, Kwang Su Kim, Jun Koseki, Rigel Suzuki, Shoya Iwanami, Yasuhisa Fujita, Yong Dam Jeong, Jumpei Ito, Hiroyuki Asakura, Mami Nagashima, Kenji Sadamasu, Kazuhisa Yoshimura, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Kei Sato, Yoshiharu Matsuura, Teppei Shimamura, Shingo Iwami, Takasuke Fukuhara. Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir. PLOS Pathogens. 19(3): e1011231. (2023)
Daisuke Akazawa, Hirofumi Ohashi, Takayuki Hishiki, Takeshi Morita, Shoya Iwanami, Kwang Su Kim, Yong Dam Jeong, Eun-Sil Park, Michiyo Kataoka, Kaho Shionoya, Junki Mifune, Kana Tsuchimoto, Shinjiro Ojima, Aa Haeruman Azam, Shogo Nakajima, Hyeongki Park, Tomoki Yoshikawa, Masayuki Shimojima, Kotaro Kiga, Shingo Iwami, Ken Maeda, Tadaki Suzuki, Hideki Ebihara, Yoshimasa Takahashi, Koichi Watashi. Potential anti-mpox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments. The Journal of Infectious Diseases. jiad058. (2023)
Daiki Tatematsu, Marwa Akao, Hyeongki Park, Shingo Iwami, Keisuke Ejima, Shoya Iwanami*. Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors. Journal of Theoretical Biology. 561:111403. (2023)
Yong Dam Jeong, Keisuke Ejima, Kwang Su Kim, Woo Joohyeon, Shoya Iwanami, Yasuhisa Fujita, Il Hyo Jung, Kazuyuki Aihara, Kenji Shibuya, Shingo Iwami, Ana I. Bento, Marco Ajelli. Designing isolation guidelines for COVID-19 patients with rapid antigen tests. Nature Communications. 13, 4910. (2022)
Keisuke Ejima, Kwang Su Kim, Ana I. Bento, Shoya Iwanami, Yasuhisa Fujita, Kazuyuki Aihara, Kenji Shibuya, Shingo Iwami. Estimation of timing of infection from longitudinal SARS-CoV-2 viral load data: mathematical modelling study. BMC Infectious Diseases. 22, 656. (2022)
Hirofumi Ohashi, Takayuki Hishiki, Daisuke Akazawa, Kwang Su Kim, Joohyeon Woo, Kaho Shionoya, Kana Tsuchimoto, Shoya Iwanami, Saya Moriyama, Hitomi Kinoshita, Souichi Yamada, Yudai Kuroda, Tsukasa Yamamoto, Noriko Kishida, Shinji Watanabe, Hideki Hasegawa, Hideki Ebihara, Tadaki Suzuki, Ken Maeda, Shuetsu Fukushi, Yoshimasa Takahashi, Shingo Iwami, Koichi Watashi. Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2. Antiviral Research. 105372. (2022)
Ryuichi Kumata, Shoya Iwanami, Katrina B. Mar, Yusuke Kakizoe, Naoko Misawa, Shinji Nakaoka, Yoshio Koyanagi, Alan S. Perelson, John W. Schoggins, Shingo Iwami*, Kei Sato*. Antithetic effect of interferon-α on cell-free and cell-to-cell HIV-1 infection. PLOS Computational Biology. 18(4): e1010053. (2022)
Makoto Yoshida, Yurie Kobashi, Takeshi Kawamura, Yuzo Shimazu, Yoshitaka Nishikawa, Fumiya Omata, Tianchen Zhao, Chika Yamamoto, Yudai Kaneko, Aya Nakayama, Morihito Takita, Naomi Ito, Moe Kawashima, Sota Sugiura, Kenji Shibuya, Shingo Iwami, Kwangsu Kim, Shoya Iwanami, Tatsuhiko Kodama, Masaharu Tsubokura. Factors Associated with COVID-19 Vaccine Booster Hesitancy: A Retrospective Cohort Study, Fukushima Vaccination Community Survey. Vaccines. 10(4):515. (2022)
Marwa Akao, Joohyeon Woo, Shingo Iwami, Shoya Iwanami*. Detection of significant antiviral drug effects on COVID-19 using viral load and PCR-positive rate in randomized controlled trials. Translational and Regulatory Sciences. Volume 3 Issue 3 Pages 85-88. (2021)
Kwang Su Kim, Shoya Iwanami, Takafumi Oda, Yasuhisa Fujita, Keiji Kuba, Taiga Miyazaki, Keisuke Ejima‡*, Shingo Iwami‡*. Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection. Life Science Alliance. 4 (10) e202101049. (2021)
Yong Dam Jeong, Keisuke Ejima†*, Kwang Su Kim, Shoya Iwanami, Ana I Bento, Yasuhisa Fujita, Il Hyo Jung, Kazuyuki Aihara, Koichi Watashi, Taiga Miyazaki, Takaji Wakita, Shingo Iwami*, Marco Ajelli. Revisiting the guidelines for ending isolation for COVID-19 patients. eLife. 10:e69340. (2021)
Shoya Iwanami, Keisuke Ejima†*, Kwang Su Kim, Koji Noshita, Yasuhisa Fujita, Taiga Miyazaki, Shigeru Kohno, Yoshitsugu Miyazaki, Shimpei Morimoto, Shinji Nakaoka, Yoshiki Koizumi, Yusuke Asai, Kazuyuki Aihara, Koichi Watashi, Robin N. Thompson, Kenji Shibuya, Katsuhito Fujiu, Alan S. Perelson, Shingo Iwami‡*, Takaji Wakita. Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study. PLOS Medicine. 18(7):e1003660. (2021)
Kaho Shionoya, Masako Yamasaki, Shoya Iwanami, Yusuke Ito, Shuetsu Fukushi, Hirofumi Ohashi, Wakana Saso, Tomohiro Tanaka, Shin Aoki, Kouji Kuramochi, Shingo Iwami, Yoshimasa Takahashi, Tadaki Suzuki, Masamichi Muramatsu, Makoto Takeda, Takaji Wakita and Koichi Watashi. Mefloquine, a potent anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) drug as an entry inhibitor in vitro. Frontiers in Microbiology. 12:651403. (2021)
Keisuke Ejima, Kwang Su Kim, Shoya Iwanami, Yasuhisa Fujita, Ming Li, Roger S. Zoh, Kazuyuki Aihara, Taiga Miyazaki, Takaji Wakita and Shingo Iwami (These authors contributed equally to this work.). Time variation in the probability of failing to detect a case of polymerase chain reaction testing for SARS-CoV-2 as estimated from a viral dynamics model. Journal of the Royal Society Interface. 18: 20200947. 20200947.. (2021)
Keisuke Ejima, Kwang Su Kim, Christina Ludema, Ana I. Bento, Shoya Iwanami, Yasuhisa Fujita, Hirofumi Ohashi, Yoshiki Koizumi, Koichi Watashi, Kazuyuki Aihara, Hiroshi Nishiura and Shingo Iwami. Estimation of the incubation period of COVID-19 using viral load data. Epidemics. 100454. (2021)
Hirofumi Ohashi, Koichi Watashi, Wakana Saso, Kaho Shionoya, Shoya Iwanami, Takatsugu Hirokawa, Tsuyoshi Shirai, Shigehiko Kanaya, Yusuke Ito, Kwang Su Kim, Takao Nomura, Tateki Suzuki, Kazane Nishioka, Shuji Ando, Keisuke Ejima, Yoshiki Koizumi, Tomohiro Tanaka, Shin Aoki, Kouji Kuramochi, Tadaki Suzuki, Takao Hashiguchi, Katsumi Maenaka, Tetsuro Matano, Masamichi Muramatsu, Masayuki Saijo, Kazuyuki Aihara, Shingo Iwami, Makoto Takeda, Jane A. McKeating and Takaji Wakita. Potential anti-COVID-19 agents, Cepharanthine and Nelfinavir, and their usage for combination treatment. iScience. 102367. (2021)
Kwang Su Kim†, Keisuke Ejima†, Shoya Iwanami, Yasuhisa Fujita, Hirofumi Ohashi, Yoshiki Koizumi, Yusuke Asai, Shinji Nakaoka, Koichi Watashi, Kazuyuki Aihara, Robin N. Thompson, Ruian Ke, Alan S. Perelson and Shingo Iwami. A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. PLOS Biology. 19(3): e3001128. (2021)
Shoya Iwanami†, Kosaku Kitagawa†, Hirofumi Ohashi, Yusuke Asai, Kaho Shionoya, Wakana Saso, Kazane Nishioka, Hisashi Inaba, Shinji Nakaoka, Takaji Wakita, Odo Diekmann, Shingo Iwami and Koichi Watashi. Should a viral genome stay in the host cell or leave? A quantitative dynamics study of how hepatitis C virus deals with this dilemma. PLOS Biology. 18(7): e3000562. (2020)
Hara A., Iwanami S., Ito Y., Miura T., Nakaoka S., and Iwami S.. Revealing uninfected and infected target cell dynamics from peripheral blood data in highly and less pathogenic simian/human immunodeficiency virus infected Rhesus macaque. Journal of Theoretical Biology. 479:29-36. (2019)
Iwanami S., Kakizoe Y., Morita S., Miura T., Nakaoka S., and Iwami S.. A highly pathogenic simian/human immunodeficiency virus effectively produces infectious virions compared with a less pathogenic virus in cell culture. Theoretical Biology and Medical Modeling. 14:9. (2017)

プレプリント

Naotoshi Nakamura, Hyeongi Park, Kwang Su Kim, Yoshitaka Sato, Yong Dam Jeong, Shoya Iwanami, Yasuhisa Fujita, Tianchen Zhao, Yuta Tani, Yoshitaka Nishikawa, Chika Yamamoto, Yurie Kobashi, Takeshi Kawamura, Akira Sugiyama, Aya Nakayama, Yudai Kaneko, Kazuyuki Aihara, Shingo Iwami, Masaharu Tsubokura. A personalized antibody score for predicting individual COVID-19 vaccine-elicited antibody levels from basic demographic and health information. medRxiv. (2022) DOI: https://doi.org/10.1101/2022.07.05.22277283
Naotoshi Nakamura, Yurie Kobashi, Kwang Su Kim, Yuta Tani, Yuzo Shimazu, Tianchen Zhao, Yoshitaka Nishikawa, Fumiya Omata, Moe Kawashima, Makoto Yoshida, Toshiki Abe, Yoshika Saito, Yuki Senoo, Saori Nonaka, Morihito Takita, Chika Yamamoto, Takeshi Kawamura, Akira Sugiyama, Aya Nakayama, Yudai Kaneko, Hyeongki Park, Yong Dam Jeong, Daiki Tatematsu, Marwa Akao, Yoshitaka Sato, Shoya Iwanami, Yasuhisa Fujita, Masatoshi Wakui, Kazuyuki Aihara, Tatsuhiko Kodama, Kenji Shibuya, Shingo Iwami, Masaharu Tsubokura. Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a community-based cohort in Fukushima, Japan. medRxiv. (2022) DOI: https://doi.org/10.1101/2022.06.11.22276266
Yong Dam Jeong, Keisuke Ejima, Kwang Su Kim, Shoya Iwanami, Shingo Iwami, Kazuyuki Aihara. Safely return to schools and offices: early and frequent screening with high sensitivity antigen tests effectively identifies COVID-19 patients. medRxiv. (2021) DOI: https://doi.org/10.1101/2021.10.08.21264782

研究費

日本医療研究開発機構 新興・再興感染症に対する革新的医薬品等開発推進研究事業, 侵襲性真菌感染症の迅速診断法と新規治療法の研究開発, 分担(代表者:宮崎泰可), 2024年04月 - 2027年03月, 9,000,000円.
日本医療研究開発機構 新興・再興感染症に対する革新的医薬品等開発推進研究事業, ドラッグリポジショニングによるエムポックス治療薬開発, 分担(代表者:日紫喜隆行), 2023年10月 - 2024年03月, 1,000,000円.
日本医療研究開発機構 新興・再興感染症に対する革新的医薬品等開発推進研究事業, 糸状菌真菌症に対する疫学調査及び革新的診断法と治療法の研究開発, 分担(代表者:宮崎泰可), 2023年07月 - 2024年03月, 2,500,000円.
日本医療研究開発機構 新興・再興感染症に対する革新的医薬品等開発推進研究事業, 新規抗サル痘ウイルス化合物の最適化とドラッグリポジショニングによる治療法の開発, 分担(代表者:日紫喜隆行), 2022年10月 - 2023年03月, 3,000,000円.
日本学術振興会 科学研究費助成事業(若手研究), 細胞群動態の変容を捉える多階層データ解析理論の構築, 代表, 2022年04月 - 2024年03月, 3,600,000円.
科学技術振興機構 戦略的創造研究推進事業(さきがけ)「パンデミックに対してレジリエントな社会・技術基盤の構築」領域, 数理科学が推進するパンデミックナレッジ基盤の構築, 代表, 2021年10月 - 2025年03月, 30,000,000円.
日本学術振興会 特別研究員奨励費, 組織維持を担う細胞群個体群動態の理解と定量的データ解析, 代表, 2019年04月 - 2021年03月, 1,700,000円.


Update: Jun 22, 2022